- Home
- Applications
- USA
- drug design and development
Refine by
Drug Design And Development Product Applications In Usa
16 applications found
DART enables near effortless inspection of tablets, powder, and liquid formulations. Qualitative and quantitative analysis are completed by using commercially available LC/MS systems from all of the major mass spectrometry vendors. Rapid reaction monitoring is facilitated with the development of our Mobile DART-Acquity QDa platform which can move from laboratory to pilot plant in minutes enabling generation of high quality information in seconds to improve your decision making process. ...
ByBruker Corporation based in Billerica, MASSACHUSETTS (USA)
When Otsuka saw a need for clinical expertise and research in the nephrology space, we decided to lead the way. For more than 20 years, we have been bringing our research and expertise to this therapeutic area. We have focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape. Our long-term perseverance has led to major breakthroughs, giving patients renewed hope and clinicians more options than ...
ByOtsuka America Pharmaceutical, Inc based in Princeton, NEW JERSEY (USA)
Effecting an estimated one million Americans, Crohn's disease can be highly debilitating and remains a serious burden for both patients and healthcare systems. ...
ByRedHill Biopharma Ltd. based in Tel-Aviv, ISRAEL
Researchers have found many uses for MALDI mass spectrometry imaging in the process of drug ...
ByHTX Technologies, LLC based in Chapel Hill,, NORTH CAROLINA (USA)
Thermal Management: Pyroid HT pyrolytic graphite thermal spreaders and thermal vias are a powerful new material solution in the battle against thermal heat in state-of-the-art electronic circuits and devices. HT material matches the heat spreading capability of CVD diamond at 1700 W/mK but at substantially better economics. ...
ByCETCO based in New York, NEW YORK (USA)
In this example, the aggregation of magnetic nanoparticles labeled with DiR is monitored in real time. Tumor microvasculature is labeled using ...
ByMauna Kea Technologies based in Paris, FRANCE
Locus has built an automated, generalizable platform that is systematically unlocking the power of bacteriophage and CRISPR-Cas3 across multiple therapeutic ...
ByLocus Biosciences, Inc. based in Morrisville, NORTH CAROLINA (USA)
High Performance Across the Breadth of Biotech. The NX One is a perfect fit for a wide variety of sectors and application areas spanning fundamental biological research to industrial and clinical workflows. Access your cells faster and at a fraction of the ...
ByNodexus Inc. based in Hayward, CALIFORNIA (USA)
Versatile blood research tool: Hemostasis monitoring of newly emerged anticoagulants especially during cardiac surgeries poses more and more challenges to standard diagnostic instrumentations. 3T developers have made pioneering contributions in QCM-D technology for the analysis of health-related whole blood parameters (Oberfrank et al, 2016; Sinn et al, 2011; 2010; Müller et al, 2010). Now the qCell T series provides a sophisticated platform with outstanding potential to face such challenging situations due ...
By3T Analytik GmbH & Co. KG based in Neuhausen ob Eck, GERMANY
DNA-based drug development and production are playing an increasingly important role in modern medicine. The application of DNA-based therapy mainly includes DNA-encoded compound library for new drugs research, genetically engineered bacterias drugs, nuelic acid vaccines, recombinant antibodies, small nucleic acid drugs, and gene editing. Firstly, we can quickly promote the development of new drugs through the construction of DNA coding libraries. Secondly, we can realize the mass production of protein drugs, ...
ByCD Biosciences - htDNA-chip® based in Shirley, NEW YORK (USA)
Facilitate the construction of human skin equivalents for wound healing research, cosmetic product development or drug delivery ...
ByRegenhu based in Villaz-St-Pierre, SWITZERLAND
Realize the value of global clinical and genomic data with us. We help reduce your risk, enhance your pipeline value and advance your enterprise data strategy by solving the barriers of data access and enabling rapid insight ...
ByBC Platforms based in Zürich, SWITZERLAND
From accelerating drug discovery to leveraging real world evidence, Centaur Labs provides life sciences innovators with high-quality medical data annotations at unprecedented speed and ...
ByCentaur Labs based in Boston, MASSACHUSETTS (USA)
Aptamers are short strands of DNA or RNA with unique secondary and tertiary structures that enable highly selective binding to various types of targets. While aptamers are similar to antibodies in their ability to specifically bind with high affinity, there are some key differences between antibodies and aptamers which have prompted an increase in aptamer development projects. Several hot areas for aptamers, along with specific aptamer advantages, are outlined below. ...
ByBase Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA)
The antibody drug discovery process differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. The production of recombinant antibodies in cancer treatment as well as the development of neutralizing antibodies for infectious diseases, has allowed antibody discovery platforms to interrogate the immune repertoire and develop novel antibody libraries using flow cytometry analysis and cell ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)
Increase clinical translation with Organ-Chips for ADME-Tox assessments. Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. However, approximately 30% of drugs fail during human clinical trials due to adverse reactions despite promising preclinical study results, and another 60% fail due to lack of efficacy. As companies broaden the modality toolbox ...
ByEmulate based in Boston, MASSACHUSETTS (USA)